IRLAB Therapeutics
31.12.2021 10:51:35 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
Board member leaves IRLAB for another assignment
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/680352/Board-Member-Leaves-IRLAB-for-Another-Assignment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Leggett Dynamics Launches Smart Brushless Motor & Advances Quiet, Software-Defined Comfort & Motion16.6.2026 13:00:00 CEST | Press release
Reduces Complexity & Cost, Improves Performance, Supports Next-Gen Architectures DETROIT, MI / ACCESS Newswire / June 16, 2026 / Leggett Dynamics today launched its Smart Brushless Motor, a next-generation motion system that simplifies design and vehicle integration, improves NVH and durability and supports evolving software architectures across seating and other motion-control applications. Less Complexity, More Capability Unlike conventional systems, Leggett Dynamics' Smart Brushless Motor can operate with or without a seat-level electronic control unit (ECU), enabling direct communication from the vehicle-level ECU to individual actuators. This streamlined approach supports the industry shift toward more centralized or zonal architectures and enables simplified, scalable integration across multiple seat configurations and trim levels with varying actuator counts. In addition, the motor's design reduces packaging size, weight, and wiring complexity while enhancing sound, durability,
Polaris Renewable Energy Reminds Shareholders to Vote Ahead of Annual Meeting16.6.2026 00:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 15, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today reminds shareholders to vote their common shares in advance of the Company's upcoming annual meeting of shareholders, which will be held virtually on June 18, 2026 at 9:00 a.m. Toronto time. Shareholders are encouraged to vote as soon as possible and prior to the proxy voting deadline of 9:00 a.m. Toronto time on June 16, 2026. Voting in advance helps ensure that shareholders' shares are represented at the meeting. At the meeting, shareholders will be asked to receive the consolidated financial statements of the Company for the year ended December 31, 2025, together with the report of the auditors thereon. Shareholders will also be asked to vote on the following matters: electing directors of the Company; and reappointing PricewaterhouseCoopers LLP, Chartered Accountants, as auditors of the Company and authorizing the directors of the Company to fix their remunerat
New Pharma AI Findings Reveal the Real Barrier to Scale: Execution, Not Innovation15.6.2026 12:00:00 CEST | Press release
GENEVA, SWITZERLAND AND WARSAW, POLAND / ACCESS Newswire / June 15, 2026 / Pharma companies are no longer struggling to identify AI opportunities - they are struggling to scale them. New findings from Lingaro, based on research with 150 senior pharma and life sciences leaders, show that AI has strong strategic visibility across the sector, yet most organizations lack the foundations needed to turn early momentum into consistent business impact. Nearly 60% of respondents say their AI strategy lacks clear ownership, highlighting a gap between leadership ambition and operational accountability. Without defined business ownership and success metrics, many companies remain stuck between experimentation and scaled delivery. Data is another barrier. According to the research, 67.3% of pharma leaders report fragmented or only partly reliable data. In a sector where commercial, medical, regulatory, and patient data often sit in disconnected systems, poor data quality can delay decisions, reduce
Litum Brings High-Precision Location Visibility to Zone 1 and Zone 2 Hazardous Environments15.6.2026 09:00:00 CEST | Press release
Combining ATEX Zone 1 and Zone 2 suitability with high-precision location capability, the ATEX Gateway and ATEX Dualis Tag set a new benchmark for intrinsically safe RTLS in hazardous industrial environments BOSTON, MA / ACCESS Newswire / June 15, 2026 / Litum, a global leader in real-time location systems, today announced the ATEX Family: a purpose-built hardware suite comprising the ATEX Gateway and ATEX Dualis Tag. Compliant with both Zone 1 and Zone 2 hazardous areas, the ATEX Family is designed to deliver sub-meter location accuracy and better visibility in environments where standard connected devices cannot be safely deployed. The launch marks a significant step forward for industrial organizations that need to track critical assets, equipment, tools, materials, and people in environments where explosive gases, vapors, or combustible dust may be present. By combining intrinsically safe design with Ultra-Wideband (UWB) and Bluetooth Low Energy (BLE) location capability, Litum ena
GA-ASI and INTEC Group Sign MOU at ILA Berlin11.6.2026 17:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / June 11, 2026 / Today at the ILA Berlin Air Show, General Atomics Aeronautical Systems, Inc. (GA-ASI) and the INTEC Group signed a Memorandum of Understanding (MoU) for INTEC to support the architecture and integration of mission systems, entry into service and logistic support services for GA-ASI's Gambit Series of Collaborative Combat Aircraft (CCA). The work is intended to provide sovereign capabilities to meet the growing interest in CCA in Germany. The MoU was signed by GA-ASI CEO Linden Blue and INTEC Group CEO Christoph Otten. GA-ASI's flight-proven Gambit CCA provides a common platform for air-to-air, air-to-ground and electronic warfare missions. Gambit is an uncrewed combat jet optimized for attack roles such as electronic warfare, Suppression of Enemy Air Defenses (SEAD), Destruction of Enemy Air Defenses (DEAD) and stand-off precision strike, making it a versatile option for evolving security needs. GA-ASI is currently flight testing the YFQ-4
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom